Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease.
Chen CD, Franklin EE, Li Y, Joseph-Mathurin N, Burns AL, Hobbs DA, McCullough AA, Schultz SA, Xiong C, Wang G, Masellis M, Hsiung GR, Gauthier S, Berman SB, Roberson ED, Honig LS, Clarnette R, Ringman JM, Galvin JE, Brooks W, Suzuki K, Black S, Levin J, Aggarwal NT, Jucker M, Frosch MP, Kofler JK, White C 3rd, Keene CD, Chen J, Daniels A, Gordon BA, Ibanez L, Karch CM, Llibre-Guerra J, McDade E, Morris JC, Supnet-Bell C, Allegri RF, Lee JH, Day GS, Lopera F, Roh JH, Schofield PR, Mills S, Benzinger TLS, Bateman RJ, Perrin RJ; DIAN-TU Study Team; DIAN-Obs Study Team.
Chen CD, et al.
Acta Neuropathol. 2025 Jun 3;149(1):57. doi: 10.1007/s00401-025-02890-7.
Acta Neuropathol. 2025.
PMID: 40459787
Free PMC article.
Clinical Trial.